TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06613204

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: STELLA-FTD Control
Description: Participants receive information about FTD and support via weekly group video-conference-based meetings.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STELLA-FTD Test
Description: The test group receives a information and support, but with a focus that is different from the Control Group
Study: NCT06613022

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instrument Assisted Soft Tissue Mobilization first Control second
Description: Instrument assisted soft tissue mobilization was utilized first on day one and wait-control was completed on second day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control first Instrument Assisted Soft Tissue Mobilization second
Description: This intervention involved waiting for 20 minutes between pre-test and post-test on day one and having Instrument Assisted Soft Tissue Mobilization on day two.
Study: NCT05117060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 152020 tablet
Description: LEO 152020 is a small drug molecule which can bind to the histamine 4 receptor (H4R) and prevent histamine from binding to the receptor. LEO 152020 is a tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 152020 tablet
Description: LEO 152020 is a small drug molecule which can bind to the histamine 4 receptor (H4R) and prevent histamine from binding to the receptor. LEO 152020 is a tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 152020 tablet
Description: LEO 152020 is a small drug molecule which can bind to the histamine 4 receptor (H4R) and prevent histamine from binding to the receptor. LEO 152020 is a tablet for oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LEO 152020 placebo tablet
Description: LEO 152020 placebo tablet contains the same excipients in the same concentration as LEO 152020 tablet, except that it does not contain the medical ingredient LEO 152020. LEO 152020 placebo is a tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 152020 placebo tablet
Description: LEO 152020 placebo tablet contains the same excipients in the same concentration as LEO 152020 tablet, except that it does not contain the medical ingredient LEO 152020. LEO 152020 placebo is a tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 152020 placebo tablet
Description: LEO 152020 placebo tablet contains the same excipients in the same concentration as LEO 152020 tablet, except that it does not contain the medical ingredient LEO 152020. LEO 152020 placebo is a tablet for oral administration.
Study: NCT04703985

Intervention type: DIETARY_SUPPLEMENT
Intervention: Enteral Nutrition
Description: Protocol of Enteral Nutrition adapted to the conditioning autograft (BEAM or Melphalan 200)
Study: NCT06228716

Intervention type: OTHER
Group type: OTHER
Intervention: Broshure
Description: Subcutaneous biological drug self-administration training was given theoretically face to face by the researcher using a power point presentation and training brochure. The training lasted approximately 25 minutes and was given in the same room where the experimental group received training. After the training, any questions the individuals had were answered and the training was ended.
Study: NCT06439108

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: single symphyseal plating in management of vertically unsable open book pelvic ring injuries
Description: open book pelvic ring injuries can be managed via the two techniques.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: single symphyseal plating in management of vertically unsable open book pelvic ring injuries
Description: open book pelvic ring injuries can be managed via the two techniques.
Study: NCT06428266

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bicanalicular intubation
Description: Placement of the bicanalicular intubation set at each lacrimal point and fixed by means of its flaps at the level of the opening of the lacrimal sac.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Closed dacryointubation
Description: Placement of dacryointubation tube through the canaliculus until it reaches the medial wall of the lacrimal sac and then passed the nasolacrimal duct until it empties out at the level of the inferior meatus.
Study: NCT05757817

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oropharyngeal or oral cavity reconstruction
Description: Oropharyngeal or oral cavity reconstruction will be performed using a free super thin external pudendal artery flap (STEPA flap).~Post-operative follow-up and adjuvant treatment: Post-operative follow-up of patients will be performed according to the standards of the participating centers.
Study: NCT06425796

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Adiposity and Iron Requirements in Pregnancy (ADIPREG)
Description: Iron 25 arm will receive: two iron supplements containing 12.5 mg of elemental iron + 1 multivitamin supplement (they will receive a total of 3 supplements per day).~Iron 50 arm will receive: two 25 mg elemental iron supplements + 1 multivitamin supplement (they will receive a total of 3 supplements per day).~The multivitamin supplement will contain folic acid, vitamin B1, vitamin B2, vitamin B3, vitamin B5, vitamin B6, vitamin B12, vitamin C and vitamin D. In summary, each participant will receive 3 supplements per day and instructed to take the 3 supplements together, in the morning, with breakfast. Supplements will be given to the participants when they attend for their clinic appointment. The intervention will begin at 12 gestational weeks and continue until the baby is delivered.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Adiposity and Iron Requirements in Pregnancy (ADIPREG)
Description: Iron 25 arm will receive: two iron supplements containing 12.5 mg of elemental iron + 1 multivitamin supplement (they will receive a total of 3 supplements per day).~Iron 50 arm will receive: two 25 mg elemental iron supplements + 1 multivitamin supplement (they will receive a total of 3 supplements per day).~The multivitamin supplement will contain folic acid, vitamin B1, vitamin B2, vitamin B3, vitamin B5, vitamin B6, vitamin B12, vitamin C and vitamin D. In summary, each participant will receive 3 supplements per day and instructed to take the 3 supplements together, in the morning, with breakfast. Supplements will be given to the participants when they attend for their clinic appointment. The intervention will begin at 12 gestational weeks and continue until the baby is delivered.
Study: NCT05702580

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Agitated Pleural Fluid Thoracentesis
Description: Using a 16-18 gauge cannula, a standard thoracentesis will be performed then a sample of pleural fluid will be aspirated and rapidly flushed into the pleural space and redrawn again for a few cycles before a sample is finally drawn into the collection syringe
Study: NCT05467852

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: didroxyprogesterone
Description: Didroxyprogesterone group: the first menstrual cycle after operation began on the 14th to 27th day of each menstrual cycle. Didroxyprogesterone 10mg bid was given orally. It was planned to use 6 menstrual cycles (if the patient was naturally pregnant during the medication, the drug could be stopped), and guide the patient to try pregnancy. The observation period was 12 menstrual cycles after operation. Control group: no drugs were used after operation, and the patients were guided to try pregnancy. The observation period was 12 menstrual cycles after operation. Subjects need to complete up to 6 follow-up visits, including the first month after operation, the first menstrual cycle d7-13 after operation, the fourth menstrual cycle d7-13 after operation, the seventh menstrual cycle d7-13 after operation, the 13th menstrual cycle d7-13 after operation and 1-2 months after termination of pregnancy
Study: NCT05332041

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Predicta Bioactive bulk fil composite restoration
Description: Predicta Bioactive bulk fil resin composite restoration material

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Predicta Bioactive bulk fil composite restoration
Description: Predicta Bioactive bulk fil resin composite restoration material
Study: NCT05927168

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: TENS will be applied to the experimental group 45 minutes before the chest tube is removed and another 15 minutes after the chest tube is removed. Patients' pain scores will be evaluated using the Numerical Pain Scale (SAS) just before the TENS procedure, while the chest tube is removed, and 5 minutes after the TENS application is finished.
Study: NCT05646927

Intervention type: PROCEDURE
Intervention: Selection of parent(mother or father) according to children preference
Description: The parent who will accompany the child during the perioperative period will be determined by children preference

Intervention type: PROCEDURE
Intervention: Selection of parent(mother or father) according to randomization
Description: The parent who will accompany the child during the perioperative period will be determined by randomization.
Study: NCT05380557

Intervention type: DIAGNOSTIC_TEST
Intervention: Germline genetic testing
Description: Germline genetic testing will be provided to each patient

Intervention type: DIAGNOSTIC_TEST
Intervention: Germline genetic testing
Description: Germline genetic testing will be provided to each patient

Intervention type: DIAGNOSTIC_TEST
Intervention: Germline genetic testing
Description: Germline genetic testing will be provided to each patient

Intervention type: DIAGNOSTIC_TEST
Intervention: Germline genetic testing
Description: Germline genetic testing will be provided to each patient
Study: NCT06010927

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine/midazolam
Description: premedication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketofol
Description: Pre-extubation
Study: NCT06130670

Intervention type: OTHER
Group type: OTHER
Intervention: nerve block
Description: Comparing the efficacy of Dexmedetomidine in bilateral quadratus lumborum block versus lumbar epidural block on postoperative analgesia following major lower abdominal cancer surgery.

Intervention type: OTHER
Group type: OTHER
Intervention: nerve block
Description: Comparing the efficacy of Dexmedetomidine in bilateral quadratus lumborum block versus lumbar epidural block on postoperative analgesia following major lower abdominal cancer surgery.
Study: NCT05861245

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 5-fraction hipofractionated protontheray
Description: The therapeutic schemes that will be proposed to patients based on clinical criteria such as tumor size and relationship of the tumor with adjacent critical organs are:~* For chordomas: 37.5 Gy in 5 consecutive sessions of 7.5 Gy per fraction.~* For chondrosarcomas: 35 Gy in 5 consecutive sessions of 7 Gy per fraction.
Study: NCT06258434

Intervention type: DIAGNOSTIC_TEST
Intervention: multiomics Colorectal Cancer (CRC) screening test (CRC-Appareo)
Description: Patients who are at high risk of developing CRC or confirmed CRC and willing to conduct colonoscopy examination will be asked to collect blood prior to bowl preparation for multiomics CRC screening test which using Reduced Representation Bisulfite Sequencing (RRBS) technology to obtain multidimensional variation information on cell-free DNA (cfDNA) methylation, end sequence, fragment size distribution, and copy number variation in the blood, and integrate analysis through machine learning algorithms to accurately assess the risk of colorectal cancer and advanced adenoma. and will be asked to collect stool sample for commercially available FIT assay. Colonoscopy and histopathologic examination are used as reference. The diagnosis information of each sample was blind to the participants who conduct the multiomics profiling, as well as the informatics who perform the integrate analysis.
Study: NCT06118905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab 60 MG/ML
Description: Subjects to receive Denosumab 60mg SQ and Zoledronic acid placebo IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic Acid 5Mg/Bag 100Ml Infusion
Description: Subjects to receive Zoledronic Acid 5mg IV and Denosumab placebo
Study: NCT05440253

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dry needling
Description: Dry needling of the trigger point of the gluteus medius in patients diagnosed with non-specific low back pain.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ischemic compression
Description: Ischaemic trigger point compression of the gluteus medius in patients diagnosed with non-specific low back pain.
Study: NCT05905107

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurodynamic Slider Technique from Proximal to Distal
Description: Neurodynamic Slider Technique from proximal to distal at wrist, elbow and neck

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neurodynamic Slider Technique from Distal to Proximal
Description: Neurodynamic Slider Technique from proximal to distal at wrist, elbow and neck
Study: NCT05841212

Intervention type: OTHER
Group type: OTHER
Intervention: DBT for ADHD
Description: See information included in arm/group description.
Study: NCT05127564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diroximel fumarate
Description: Administered as specified in the treatment arm
Study: NCT05862428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rectal misoprostol
Description: This intervention group receive Misoprostol transrectally before undergoing total abdominal hysterectomy
Study: NCT05910905

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prefabricated pediatric zirconia crown group
Description: Zirconia crown application: After preparing the molars, the crown was cemented by passive seating with modified glass ionomer cement (GC FujiCEM Evolve, GC America, Alsip, USA).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prefabricated stainless steel crown group
Description: Stainless steel crown application: After preparing the molars, the crown was filled with type-1 glass ionomer cement (Aqua Meron, Voco, Cuxhaven, Germany) and cemented.
Study: NCT05985057

Intervention type: OTHER
Intervention: Artificial intelligence
Description: Prediction of carbapenem resistance via deep machine learning model

Intervention type: OTHER
Intervention: Artificial intelligence
Description: Prediction of carbapenem resistance via deep machine learning model
Study: NCT06219863

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Body weight supported harness
Description: A body weight supported harness will be provided to families for one month to set up in their home. Caregivers will be asked to use the harness for their infants for 30 min per day, 5 days a week. Caregivers will complete a daily log describing harness use. At the end of the month, they will complete feasibility and acceptability questionnaires.
Study: NCT05097196

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic activities
Description: The exercise intensity of the individual is planned at 50-60% heart rate reserve using the Karvonen method.
Study: NCT05240326

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise training group
Description: All exercise program will be applied during supervised session by a physiotherapist. Clinical pilates exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks. The program consisted of 10 minutes warm-up exercises, clinical pilates-based exercises on mat for 40 minutes and 10 minutes relaxation and stretching exercises.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: control training group
Description: The control group will be followed up as a home program by giving the relaxation exercises. Patients will be asked to do the exercises regularly for 3 days/week, 1 sessions/day, for eight weeks. Patients in the control group will be followed up by phone once a week.
Study: NCT05648929

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Satisfaction Questionnaire
Description: During regular clinical examinations patient will go through a short questionnaire at week 4, 16 and 24 to check patient satisfaction with expanders

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Satisfaction Questionnaire
Description: During regular clinical examinations patient will go through a short questionnaire at week 4, 16 and 24 to check patient satisfaction with expanders

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Pregnancy test
Description: Pre-op; to sufficiently check pregnancy as exclusion criteria

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Pregnancy test
Description: Pre-op; to sufficiently check pregnancy as exclusion criteria

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood draw
Description: pre- expander implantation, alongside anaesthesia pre- expander explantation and exchange with definite implant alongside anaesthesia - no additional vein irritation needed

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood draw
Description: pre- expander implantation, alongside anaesthesia pre- expander explantation and exchange with definite implant alongside anaesthesia - no additional vein irritation needed

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Expander based breast reconstruction
Description: implantation of 2 different expanders intraindividually

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Expander based breast reconstruction
Description: implantation of 2 different expanders intraindividually

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound of breast
Description: Measurement of capsular thickness pre- expander removal

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound of breast
Description: Measurement of capsular thickness pre- expander removal

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: S(AE )monitoring
Description: (S)AE evaluation will be performed from Visit 1 (Day 0 = Expander implantation) to Visit 15 (Day 168-196 = Reoperation) according to visit plan.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: S(AE )monitoring
Description: (S)AE evaluation will be performed from Visit 1 (Day 0 = Expander implantation) to Visit 15 (Day 168-196 = Reoperation) according to visit plan.
Study: NCT05252442

Intervention type: OTHER
Intervention: Pre-COVID-19
Description: Pre-COVID-19 period

Intervention type: OTHER
Intervention: COVID-19
Description: COVID-19 period

Intervention type: OTHER
Intervention: COVID-19 vaccination roll-out
Description: COVID-19 vaccination roll-out period
Study: NCT05884177

Intervention type: OTHER
Intervention: Short-term cold exposure
Description: Short-term cold exposure

Intervention type: OTHER
Intervention: Short-term cold exposure
Description: Short-term cold exposure
Study: NCT05802823

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized Simülation Patient
Description: There are preliminary information, information, application and analysis sessions in the research. A rehearsal will be made 10 days before the application and arrangements will be made if necessary. The students will be given the resources 1 week before the application and the scenario 5 minutes before the application and informed consent will be obtained. Just before the application, information about the simulation process and analysis will be given. Students will be divided into 6 groups with the random numbers table and the application will be made on different days and times. The application time is 10-15 minutes and the camera will be recorded during the interview. At the end of the application, standard patient feedback will be given for each student. At the end of the application, analysis sessions will be held with the students as a group and feedback will be given by peers and trainers about their own performances. Analysis sessions will take between 30-45 minutes.
Study: NCT06225505

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: ctDNA monitoring
Description: For each patient included, a ctDNA detection assay will be performed in blood samples every 3 months, while extra-plasma will be banked. ctDNA results will be available with a turnaround time of less than 3 weeks. When negative, ctDNA detection results will not be disclosed to patients nor clinicians.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ctDNA monitoring
Description: For each patient included, a ctDNA detection assay will be performed in blood samples every 3 months, while extra-plasma will be banked. ctDNA results will be available with a turnaround time of less than 3 weeks. When negative, ctDNA detection results will not be disclosed to patients nor clinicians.

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: 68Ga-FAPI-46-PET-CT
Description: ). To locate metastatic deposits, patients will be offered to undergo a whole-body imaging with 18F-FDG PET-CT and 68Ga-FAPI-46-PET-CT, in addition to any other workup considered as relevant by their treating physician.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI-46-PET-CT
Description: ). To locate metastatic deposits, patients will be offered to undergo a whole-body imaging with 18F-FDG PET-CT and 68Ga-FAPI-46-PET-CT, in addition to any other workup considered as relevant by their treating physician.
Study: NCT04863482

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IOC
Description: intra-operative cholangiography near-infrared fluorescence cholangiography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IOC
Description: intra-operative cholangiography near-infrared fluorescence cholangiography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IOC
Description: intra-operative cholangiography near-infrared fluorescence cholangiography
Study: NCT06154304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol Sulfate Inhalation Aerosol (90 mcg per actuation)
Description: 90 mcg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ventolin HFA 90Mcg/Actuation Inhalation Aerosol_#1
Description: 90 mcg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ventolin HFA, 90 Mcg/Inh Inhalation Aerosol_#2
Description: 180 mcg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05251350

Intervention type: PROCEDURE
Intervention: surgery
Description: our study is observational and we use secondary data
Study: NCT05121610

Intervention type: PROCEDURE
Intervention: The procedures include PCI, CABG and HCR
Description: The procedures include PCI, CABG and HCR

Intervention type: PROCEDURE
Intervention: The procedures include PCI, CABG and HCR
Description: The procedures include PCI, CABG and HCR

Intervention type: PROCEDURE
Intervention: The procedures include PCI, CABG and HCR
Description: The procedures include PCI, CABG and HCR